CN102149375B - 人肾上腺素β3受体配体、含有其的食品及药品 - Google Patents

人肾上腺素β3受体配体、含有其的食品及药品 Download PDF

Info

Publication number
CN102149375B
CN102149375B CN200980131312.3A CN200980131312A CN102149375B CN 102149375 B CN102149375 B CN 102149375B CN 200980131312 A CN200980131312 A CN 200980131312A CN 102149375 B CN102149375 B CN 102149375B
Authority
CN
China
Prior art keywords
acid
fatty acid
day
component
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980131312.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102149375A (zh
Inventor
藤本康雄
栗原昭一
浜屋忠生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KK Tone
Original Assignee
KK Tone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KK Tone filed Critical KK Tone
Publication of CN102149375A publication Critical patent/CN102149375A/zh
Application granted granted Critical
Publication of CN102149375B publication Critical patent/CN102149375B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN200980131312.3A 2008-06-11 2009-06-11 人肾上腺素β3受体配体、含有其的食品及药品 Expired - Fee Related CN102149375B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008153390 2008-06-11
JP2008-153390 2008-06-11
PCT/JP2009/060682 WO2009151094A1 (ja) 2008-06-11 2009-06-11 ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品

Publications (2)

Publication Number Publication Date
CN102149375A CN102149375A (zh) 2011-08-10
CN102149375B true CN102149375B (zh) 2015-09-30

Family

ID=41416798

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980131312.3A Expired - Fee Related CN102149375B (zh) 2008-06-11 2009-06-11 人肾上腺素β3受体配体、含有其的食品及药品

Country Status (7)

Country Link
US (1) US20110098358A1 (enExample)
EP (1) EP2316445A4 (enExample)
JP (2) JP5544660B2 (enExample)
KR (1) KR101274543B1 (enExample)
CN (1) CN102149375B (enExample)
CA (1) CA2727223C (enExample)
WO (1) WO2009151094A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071180A1 (en) * 2014-11-03 2016-05-12 Nestec S.A. Methods using facial temperature to evaluate post-ingestive impact of food ingredients on fat oxidation
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020146263A1 (en) 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
JP7500037B2 (ja) * 2019-07-24 2024-06-17 国立大学法人 東京大学 血中尿酸値低下剤及び血中尿酸値低下用食品組成物
US12370166B2 (en) 2021-11-03 2025-07-29 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005179264A (ja) * 2003-12-19 2005-07-07 Shokubutsu Kogaku Kenkyusho:Kk 体重増加抑制剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173545C (en) * 1995-04-07 2004-06-29 Kalyana Sundram Increasing the hdl level and the hdl/ldl ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
US7687074B2 (en) * 2001-08-23 2010-03-30 Westgate Biological Ltd. Use of milk serum apoproteins in the treatment of microbial or viral infection
WO2003099304A1 (en) * 2002-05-27 2003-12-04 Morinaga & Co., Ltd. Composition against periodontal bacteria and foods, drinks and mouth washers against periodontal bacteria containing the composition
JP2004075653A (ja) * 2002-06-19 2004-03-11 Nisshin Oillio Ltd 体脂肪分解促進剤および飲食物
AU2003261926A1 (en) * 2002-09-05 2004-03-29 The Nisshin Oillio Group, Ltd. Slimming agents and foods and drinks comprising the same
JPWO2004022050A1 (ja) * 2002-09-05 2005-12-22 日清オイリオグループ株式会社 脂質代謝調整剤および飲食物
CN1330671C (zh) 2002-10-08 2007-08-08 株式会社利根 含脱乙酰壳多糖的多糖、其制备方法和用途
JP2006096666A (ja) 2002-10-31 2006-04-13 Kaneka Corp 選択的ヒトβ３アドレナリン受容体アゴニスト剤
JP2005015358A (ja) * 2003-06-25 2005-01-20 Pharma Design Inc 摂食障害の治療に供される医薬組成物
AU2004285803A1 (en) * 2003-11-04 2005-05-12 Meiji Dairies Corporation Plant-origin beta3-adrenoceptor agonist and use of the same
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
EP1834639B8 (en) * 2005-01-04 2016-12-07 Mochida Pharmaceutical Co., Ltd. Remedial agent for fat toxicity
US20080200707A1 (en) * 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
GB0514463D0 (en) * 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid
US20090203780A1 (en) * 2006-06-27 2009-08-13 Luisa Gambelli Use of a Polyunsaturated Fatty Acid Compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005179264A (ja) * 2003-12-19 2005-07-07 Shokubutsu Kogaku Kenkyusho:Kk 体重増加抑制剤

Also Published As

Publication number Publication date
JP5544660B2 (ja) 2014-07-09
EP2316445A4 (en) 2011-12-21
JPWO2009151094A1 (ja) 2011-11-17
KR20110017437A (ko) 2011-02-21
US20110098358A1 (en) 2011-04-28
JP2014080432A (ja) 2014-05-08
EP2316445A1 (en) 2011-05-04
CA2727223C (en) 2014-10-07
WO2009151094A1 (ja) 2009-12-17
CN102149375A (zh) 2011-08-10
KR101274543B1 (ko) 2013-06-17
CA2727223A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
CN102149375B (zh) 人肾上腺素β3受体配体、含有其的食品及药品
CN100431537C (zh) 血液流动性改善剂
CN108619283B (zh) 一种用于改善脂质代谢、减少内脏脂肪的组合物
JP5711616B2 (ja) Ｉｌ−１７産生抑制剤
JP6145352B2 (ja) 納豆菌を用いたマコンブ発酵物の血圧上昇抑制剤
CA2966574C (en) Agents for maintaining undifferentiated state and promoting proliferation of stem cells
HK1157216A (en) Human b3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
CN112168812B (zh) 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途
JP5599020B2 (ja) ミトコンドリア融合剤
US20100028465A1 (en) Composition for ameliorating cerebral function
WO2007040006A1 (ja) ペルオキシソーム増殖剤応答性受容体ＰＰＡＲγ活性化剤、および該活性化剤を含有する特定症状の予防または改善用組成物
KR101495607B1 (ko) Ｓ-아릴 시스테인을 유효성분으로 함유하는 비만으로 유도된 염증 치료용 조성물
JP2019172614A (ja) 遺伝子発現制御剤及び筋委縮の抑制剤、予防剤又は改善剤
JP6145353B2 (ja) Ｌａｃｔｏｂａｃｉｌｌｕｓ属を用いた発酵ヒダカコンブの血圧上昇抑制剤
JP7748715B2 (ja) 線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物
KR20140086213A (ko) 에보디아민을 유효성분으로 함유하는 비만으로 유도된 염증 치료용 조성물
KR102717836B1 (ko) 자소엽에서 분리한 화합물을 유효성분으로 포함하는 자가면역질환 예방 및 치료용 조성물
JP2009084211A (ja) 神経細胞賦活組成物
JP5366386B2 (ja) 神経細胞賦活及び神経伸長促進用組成物
WO2015150966A1 (en) Food supplement composition comprising a cucumber (cucumis sativus) extract
JP6420645B2 (ja) ＰＧＣ１α発現促進剤
JP3917825B2 (ja) 血管新生抑制剤
JP5991836B2 (ja) ギンコライドと魚介油を含有する組成物
JP2022119222A (ja) 腸内短鎖脂肪酸増加剤及び腸内への酪酸伝達システム
JP2010095456A (ja) 脂質代謝改善剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157216

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1157216

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150930